Audio Conference: COVID-19's Impact on Lab Industry Testing Volumes and Dynamics

COVID-19's Impact on Lab Industry Testing Volumes and Dynamics

UBS invites you to listen to the 1 hour audio conference recording, "COVID-19's Impact on Lab Industry Testing Volumes and Dynamics," to hear UBS Research Analysts and XIFIN Executives discuss how COVID-19 has impacted laboratory and diagnostic testing industry in the short and long term. 

Key Takeaways:

  • Learn how Laboratory and Diagnostic Testing Volumes have trended since the beginning of the COVID-19 outbreak from a company that processes over $40bn of gross diagnostic claims annually
  • Learn how the COVID-19 outbreak has impacted diagnostic volumes, mix, and reimbursement for a variety of diagnostic providers (hospital, regional, reference, and national providers)
  • Understand the specific constraints on increased COVID-19 testing in the short-term and how diagnostic providers are budgeting for a potential ramp in COVID-19 PCR, Sequencing, Serology, and Point-of-care testing
  • Understand the financial conditions of the variety of diagnostic providers and how the COVID-19 outbreak might impact industry dynamics in both the short and long term

UBS Speakers

  • Kevin Caliendo, UBS Healthcare Supply Chain & HCIT Senior Analyst
  • Dan Brennan, UBS Life Science Tools & Diagnostics Senior Analyst
  • ​Matt Taylor, CFA, UBS US Medical Supplies & Devices
  • Whit Mayo, UBS Healthcare Services and Managed Care Analyst

XIFIN Featured Speakers

Lâle White
Executive Chairman & CEO
XIFIN, Inc. 

Kyle Fetter
Executive Vice President & General Manager of Diagnostic Services
XIFIN, Inc. 


UBS Genomics Summit